Goldman Sachs previews 2Q results for Americas biotechnology: Macro and company-specific catalysts jointly drive sector performance
AI summary card
Goldman Sachs previews 2Q results for Americas biotechnology: Macro and company-specific catalysts jointly drive sector performance
The report notes that XBI has significantly outperformed the healthcare sector and the broader market year to date, primarily driven by an M&A recovery, innovation trends, declining regulatory risk, and macro rotation; after 2Q results, market attention will shift toward key companies' pipelines, commercialization execution, and clinical/regulatory catalysts from 2H26 through 1H27.
- XBI is up approximately 15% year to date, outperforming the S&P 500 and leading XLV by approximately 21 percentage points; large-cap biotechnology stocks overall are close to the broader market, but dispersion among individual stocks is significant.
- Biopharma M&A transaction value has reached approximately $143 billion year to date in 2026, approaching the 2025 full-year level of $200 billion; the report believes the subsequent M&A environment remains favorable.
- Key debated companies include AMGN, BIIB, GILD, REGN, VRTX, and ALNY, with market attention extending beyond 2Q results to subsequent narratives involving Lp(a), MariTide, Yeztugo, Eylea, and SION data.
- Goldman Sachs updated its models to reflect 10-Q filings, IPR&D, prescription trends, and management commentary, but said the adjustments had limited impact on forecasts and target prices; investment theses and ratings remain unchanged.
Report interpretation
Overview
This report is Goldman Sachs' 2Q earnings preview for the biotechnology industry within the Americas healthcare sector. It decomposes sector performance into macro rotation, M&A activity, innovation trends, changes in regulatory/development risk, and company-specific clinical and commercialization catalysts. The core view is that large-cap biotechnology stocks have generally tracked the market year to date, while the broader biotechnology sector has clearly outperformed healthcare and the broader market, with subsequent performance still determined jointly by the macro environment and company-specific events.
Core views
The report believes that biotechnology sector strength is driven by three themes: first, M&A has clearly recovered, with approximately $143 billion in disclosed transaction value year to date, and Goldman Sachs believes conditions remain favorable for continued M&A activity; second, innovation trends remain strong, with regulatory and development risks declining for certain companies, despite continued negative clinical surprises; and third, macro and rotation factors related to AI, geopolitical trading, interest rates, and improving capital markets activity continue to influence fund flows. In the near term, 2Q earnings may provide a window for large-cap biopharma to outperform temporarily, but investors are more focused on the narrative shift after earnings, including AMGN's Lp(a) and MariTide, BIIB's EPS and portfolio dynamics following the integration of APLS, GILD's Yeztugo/HIV, REGN's Eylea and SNY partnership, VRTX's SION data pressure, and ALNY's cardiovascular theme before and after the ESC conference.
Analysis framework
The report combines sector performance comparisons, earnings forecast revisions, comparisons between GSe and consensus expectations, reviews of M&A transactions, a calendar of key pipeline/regulatory catalysts, and updates to company models. For early-stage biotechnology companies, the report also uses assumptions for probability of success, WACC, terminal growth rate, and peak sales in sensitivity analyses to assess the impact of key programs on valuation.
Methodology notes
Compares the year-to-date performance of XBI, large-cap biotechnology, XLV, the S&P 500, and QQQ.
This framework is used to determine whether biotechnology outperformance is driven by industry fundamentals, macro rotation, or changes in market style.
Tracks clinical data, PDUFA, BLA/IND, commercialization updates, and investor conferences from 2H26 through 1H27.
Biotechnology company valuations typically depend heavily on clinical, regulatory, and commercialization milestones; the report uses a catalyst list to identify short- and medium-term stock price triggers.
Calculates the impact of changes in probability of success on target prices or valuation ranges under bear- and bull-market discounting assumptions.
This method is particularly applied to early-stage pipeline companies such as ALLO, BIOA, CLLS, and PRME to illustrate the valuation leverage of individual program success probabilities.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- XBIA representative biotechnology sector ETF, used by the report to measure broad biotechnology performance.
- Strengths
- Up approximately 15% year to date, significantly outperforming the healthcare sector and the broader market, supported by M&A, innovation, and macro rotation.
- Weaknesses
- Dispersion among individual stocks within the sector is significant, and performance remains affected by clinical failures, regulatory uncertainty, and interest rates.
- Comparison
- Significantly outperformed the S&P 500 and XLV, and also outperformed large-cap biotechnology.
- Risks
- A reversal in macro rotation, cooling capital markets, negative clinical data, or rising regulatory risk.
- XLVHealthcare sector benchmark, used by the report as a reference for biotechnology's relative performance.
- Strengths
- Relatively defensive characteristics and suitable as a sector benchmark.
- Weaknesses
- Year-to-date performance is weaker than that of XBI and large-cap biotechnology.
- Comparison
- XBI has outperformed XLV by approximately 21 percentage points, while large-cap biotechnology has outperformed XLV by approximately 4 percentage points.
- Risks
- If capital continues to rotate from healthcare toward higher-beta biotechnology, XLV's relative performance could remain under pressure.
- AMGNA key company for 2Q earnings and subsequent pipeline debates.
- Strengths
- Potential 2Q earnings beat, with multiple subsequent program milestones involving Lp(a), MariTide, Tezspire, and dazodalibep.
- Weaknesses
- Investor focus could quickly shift from earnings to pipeline execution, with expectations pressure surrounding MariTide and Lp(a) readouts.
- Comparison
- A large-cap biopharma name driven by both earnings and pipeline catalysts.
- Risks
- Key clinical data falling short of expectations, intensifying obesity/cardiovascular competition, or downward revisions to pipeline valuations.
- GILDA focal point for 2Q debates and HIV commercialization/pipeline developments.
- Strengths
- The Yeztugo for PrEP launch, HIV programs, and Trodelvy/Anito-cel portfolio provide subsequent catalysts.
- Weaknesses
- The report notes considerable market debate surrounding Yeztugo and HIV trends, as well as increased short interest.
- Comparison
- Goldman Sachs expects the 2Q report to be broadly in line with expectations.
- Risks
- Yeztugo uptake falling short of expectations, HIV competition, or key indication data failing to meet targets.
- REGNA focus among large-cap biotechnology companies for commercialization and partnership developments.
- Strengths
- Eylea, cemdisiran, garetosmab, the Dupixent lifecycle, and multiple Phase 3 programs provide a rich set of catalysts.
- Weaknesses
- Eylea revenue and clarity regarding the partnership with SNY remain primary areas of focus.
- Comparison
- Unlike companies with single pipelines, REGN is simultaneously driven by commercialization, partnerships, and clinical data.
- Risks
- Eylea competition, supply or regulatory delays, uncertainty around the SNY partnership, or Phase 3 data failures.
- ALNYA cardiovascular-themed name focused on 2Q earnings and developments before and after the ESC conference.
- Strengths
- Goldman Sachs expects 2Q to be in line with or better than expectations, with strong ex-US drivers; ALN-6400, nucresiran, and mivelsiran are among the pipelines under focus.
- Weaknesses
- Near-term attention has shifted to ESC and subsequent pipeline data, so earnings themselves may not be the primary driver.
- Comparison
- Highly relevant to the cardiovascular theme and an important sector catalyst name.
- Risks
- ESC or pipeline data falling short of expectations, development timeline delays, or intensifying competition.
- ELVN, DNLI, RLAY, TSHA, RAPPNames identified in the report as related to M&A optionality.
- Strengths
- Potential acquisition appeal or strategic asset characteristics.
- Weaknesses
- M&A optionality is difficult to verify and cannot substitute for fundamental execution.
- Comparison
- More driven by events and risk appetite.
- Risks
- M&A expectations failing to materialize, insufficient asset data, or declining market risk appetite.
Key data
- XBI year-to-date performance+15%The report says XBI has significantly outperformed the S&P 500, XLV, and QQQ.
- XBI relative performance versus XLV+21 percentage pointsThe broader biotechnology sector is significantly stronger than the healthcare sector.
- Large-cap biotechnology relative to healthcare+4% vs. XLVLarge-cap biotechnology has generally tracked the broader market year to date but has outperformed XLV.
- Biopharma M&A transaction value year to date in 2026$143bnThe report compares this with approximately $200bn for full-year 2025 and believes the environment remains favorable for subsequent M&A activity.
- Impact of 2Q model updatesLimitedGoldman Sachs said that after updating for 10-Q filings, IPR&D, prescription trends, and management commentary, several forecasts and target prices were affected only modestly, with ratings and investment theses unchanged.
- Pricing data date2026-07-17 closeThe target price framework in the report is 12 months.
Impact & implications
For investors, the report implies that near-term biotechnology sector trading is not solely an earnings trade, but rather a combination of macro rotation, M&A expectations, clinical data, and regulatory milestones. At the sector level, improving M&A and capital markets could continue to support risk appetite; at the individual-stock level, clinical data quality, regulatory pathway clarity, commercialization execution, and M&A optionality will determine dispersion. The report specifically highlights ELVN, DNLI, RLAY, TSHA, and RAPP as having M&A optionality, while subsequent key catalysts for SMMT and MRNA also merit attention.
Risks
- Changes in macro rotation and the interest-rate environment could weaken risk appetite for biotechnology.
- Clinical data, PDUFA, BLA/IND, or regulatory communications falling short of expectations could trigger significant volatility in individual stocks.
- If the recovery in M&A transactions slows, valuation support for the sector could weaken.
- Early-stage biotechnology valuations depend heavily on PoS, WACC, TGR, and peak-sales assumptions, and changes in these parameters can amplify target-price sensitivity.
- Commercialization-focused companies face risks related to prescription trends, the competitive landscape, reimbursement, and launch timing.
What to watch
- AMGN updates in 2H26 and beyond regarding Lp(a), MariTide, Tezspire, dazodalibep, and related Phase 3/Phase 2 data.
- The GILD Yeztugo launch, complete HIV program data at AIDS2026, and subsequent milestones for Anito-cel and Trodelvy.
- REGN's Eylea HD prefilled syringe, cemdisiran, garetosmab, C5 combination, fianlimab+Libtayo, and progress in its partnership with SNY.
- ALNY's cardiovascular theme before and after the ESC conference, as well as data for ALN-6400, ALN-HTT02, and ALN-2232.
- Final PFS and interim OS results from SMMT's HARMONi-3.
- MRNA data from 2H26 through 1H27 for oncology vaccines, influenza, norovirus, and rare diseases.
- Clinical and strategic developments for potential M&A-related names including ELVN, DNLI, RLAY, TSHA, and RAPP.